US Patent

US9156795 — Hydrogen sulfate salt

Composition of Matter · Assigned to AstraZeneca AB · Expires 2026-12-12 · 1y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects the hydrogen sulfate salt and various forms of Compound 1, including crystalline and amorphous forms, and methods for preparing them.

USPTO Abstract

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: US9156795
Jurisdiction: US
Classification: Composition of Matter
Expires: 2026-12-12
Drug substance claim: Yes
Drug product claim: Yes
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.